This study tests if a new drug, RL-007, helps people with schizophrenia think better. Schizophrenia is a brain disorder that affects how a person thinks, feels, and behaves. During this study, participants will take either RL-007 or a placebo, which is a pill with no active drug, for six weeks. They will do thinking tasks before and after the treatment to see if there is any improvement. The study also checks which dose, either 20 mg or 40 mg, works better. Safety checks like blood pressure and heart tests will be done regularly to ensure participants are safe.

Key Points:

• The study lasts for 6 weeks with regular safety checkups.
• Participants must have stable schizophrenia and be on a steady dose of medication.
• People with other major disorders or recent hospitalizations cannot join.

Participants must speak English well and have stable housing during the study. They should not have recent substance abuse or severe mental health issues. If you fit the criteria and want to help test RL-007, this study could be for you!